Adeia Enters into License Renewal with Mitsubishi Electric
May 14, 2024 08:30 ET
|
Adeia Inc.
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), the company whose patented innovations shape the way the world explores and experiences entertainment, today announced...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13, 2024 07:00 ET
|
Fulcrum Therapeutics, Inc.
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 13, 2024 06:00 ET
|
Fulcrum Therapeutics, Inc.
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024 06:00 ET
|
AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...
Hudson Technologies Enters Into Licensing Agreement With Chemours
May 06, 2024 08:30 ET
|
Hudson Technologies
WOODCLIFF LAKE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Hudson Technologies, Inc. (NASDAQ: HDSN) a leading provider of innovative and sustainable refrigerant products and services to the Heating,...
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
May 01, 2024 06:25 ET
|
G1 Therapeutics
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
Copenhagen Infrastructure Partners secures two offshore wind feasibility licences in Australia and launches new platform company
May 01, 2024 04:00 ET
|
Copenhagen Infrastructure Partners
CIP secures two offshore wind feasibility licences in Australia and launches new platform company
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
April 30, 2024 09:01 ET
|
ARS Pharmaceuticals, Inc.
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat...
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
April 29, 2024 09:45 ET
|
Elevai Labs Inc.
Elevai Labs Releases Global Distribution Partnership Overview: Contracts Secure $11.5M Top Line Revenue Boost